+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Extreme suppression of HIV-1 plasma RNA using a combination of zidovudine, didanosine, zalcitabine, epivir, saquinavir, and interferon-alpha in subjects with HIV-1 infection



Extreme suppression of HIV-1 plasma RNA using a combination of zidovudine, didanosine, zalcitabine, epivir, saquinavir, and interferon-alpha in subjects with HIV-1 infection



ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Author Eleventh International Conference on AIDS, Vol Two One world: One hope : 78




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 031402237

Download citation: RISBibTeXText


Related references

Dramatic suppression of HIV-1 plasma RNA using a combination of zidovudine, didanosine, zalcitabine, epivir, and interferon-alpha in subjects with recent HIV-1 infection. ELEVENTH INTERNATIONAL CONFERENCE ON AIDS Author Eleventh International Conference on AIDS, Vol Two One world: One hope : 29, 1996

Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group. Aids 13(7): 851-858, 1999

Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. Journal of Infectious Diseases 179(1): 249-253, 1999

Resistance Mutations to Zidovudine and Saquinavir in Patients Receiving Zidovudine Plus Saquinavir or Zidovudine and Zalcitabine Plus Saquinavir in Aids Clinical Trials Group 229. The Journal of Infectious Diseases 179(1): 249-253, 1999

Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells/mm3. Antiviral Therapy 4(1): 35-44, 1999

Saquinavir + zalcitabine vs saquinavir or zalcitabine monotherapy in HIV-infected patients discontinuing or intolerant to zidovudine Results of a randomized, double blind trial. AIDS (London) 10(Suppl. 2): S17, 1996

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus zalcitabine is preferred to zidovudine plus didanosine. Reviews in Medical Virology 4(1): 5-8, 1994

In HIV-infected individuals who desire combination antiviral therapy, zidovudine plus didanosine is preferred to zidovudine plus zalcitabine. Reviews in Medical Virology 4(1): 9-12, 1994

Virologic and immunologic benefits of initial combination therapy with zidovudine and zalcitabine or didanosine compared with zidovudine monotherapy. Journal of Infectious Diseases 173(6): 1354-1366, 1996

Retrospective study of zidovudine or didanosine monotherapy or zalcitabine plus zidovudine combination therapy in patients with early AIDS. TENTH INTERNATIONAL CONFERENCE ON AIDS, INTERNATIONAL CONFERENCE ON STD [Author] Tenth International Conference on AIDS and the International Conference on STD, Vol 1; The global challenge of AIDS: Together for the future : 1) 209, 1994

Evolution of HIV drug resistance in zidovudine/zalcitabine- and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy 3(2): 81-88, 1998

Studies of zidovudine in combination with didanosine and zalcitabine. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 10(Suppl. 1): S52, 1995

Zidovudine and interferon-alpha combination therapy versus zidovudine monotherapy in subjects with symptomatic human immunodeficiency virus type 1 infection. Journal of Infectious Diseases 169(6): 1351-1355, 1994

Pharmacokinetics of saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents and ChemoTherapy 41(11): 2428-2432, 1997

Exposure-response relationships for saquinavir, zidovudine, and zalcitabine in combination therapy. Antimicrobial Agents and ChemoTherapy 41(11): 2433-2438, 1997